Adverum Biotechnologies Inc.

About Adverum Biotechnologies Inc.

Adverum Biotechnologies is dedicated to redefining sight for life by developing gene therapies as a new standard of care for debilitating ocular diseases. Their mission is to restore vision and prevent blindness through innovative treatments, aspiring to create functional cures and transform the standard of care for highly prevalent ocular conditions.

Products & Services

Ixo-vec:An investigational gene therapy for wet age-related macular degeneration (wet AMD), designed as a single-administration intravitreal therapy to extend treatment benefits from weeks to years, transforming retinal cells into biofactories that produce therapeutic doses of aflibercept, an anti-VEGF treatment.

Specialties

Gene Therapy Ocular Diseases Wet Age-Related Macular Degeneration (wet AMD) Adeno-Associated Virus (AAV) Vector Platform Intravitreal (IVT) Therapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 127500000 MR: - FA: $127.5 million FAN: 127500000	D: 2024-02-05 FD: 2024-02-05	9 investors

Private Placement Latest

2024-02-05

$127.5M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Laurent Fischer, M.D.

President and Chief Executive Officer

R

Romuald Corbau

Chief Scientific Officer

A

Aneta Ferguson

General Counsel

C

Carla Fiankan

Senior Vice President, Regulatory Affairs

D

Dena House

Chief People Officer

H

Heikki Jouttijärvi

Senior Vice President, Manufacturing and Supply Chain Management

View 24 more team members with Pro

Unlock Full Team Directory

Recent News